Roxadustat: Do we know all the answers?

Roxadustat: Do we know all the answers?

Anemia is a common complication of chronic kidney disease (CKD), and its prevalence rises as the disease progresses. Intravenous or subcutaneous erythropoiesis-stimulating agents (ESAs) are advised to treat CKD-associated anemia, since shortage of erythropoietin (EPO) and iron are the main cause of...

Full description

Bibliographic Details
Main Authors: Qiu-Yu Li, Qian-Wen Xiong, Xuefeng Yao, Fei Liu, Xiaoxiao Tang, Haidong Fu, Tong Tong, Jianhua Mao, Wan-Xin Peng
Format: Article
Language:English
Published: Association of Basic Medical Sciences of Federation of Bosnia and Herzegovina 2023-05-01
Series:Biomolecules & Biomedicine
Subjects:
Erythropoietin
HIF-PHI
roxadustat
renal anemia
therapeutic potential
Online Access:https://www.bjbms.org/ojs/index.php/bjbms/article/view/8437

Internet

https://www.bjbms.org/ojs/index.php/bjbms/article/view/8437

Similar Items